Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPCGSD)

• Drug Name: 2,3-dichloro-1,4-naphthoquinone Drug Info
• Synonyms: 2,3-Dichloro-1,4-naphthoquinone; 117-80-6; DICHLONE; 2,3-dichloronaphthalene-1,4-dione; Diclone; 2,3-Dichloronaphthoquinone; Phygon; Uniroyal; Sanquinon; Algistat; Phygon paste; Dichloronaphthoquinone; Phygon XL; Quintar; Compound 604; 1,4-Naphthalenedione, 2,3-dichloro-; Phygon seed protectant; U.s. rubber 604; Quintar 540F; Dichlon; USR 604; 2,3-Dichloro-1,4-naphthaquinone; 2,3-Dichloro-1,4-naphthalenedione; Caswell No. 298; ENT 3,776; 1,4-Naphthoquinone, 2,3-dichloro-; US Rubber 604; Latka 604; Dichlone [BSI:ISO]; Latka 604 [Czech]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 8342
  CAS Number: CAS 117-80-6
  TTD Drug ID: DMPCGSD

Molecule-Related Drug Atlas

Drug(s) Targeting Indoleamine 2,3-dioxygenase 1 (IDO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Tryptophan	DMIBH7M	Depression	6A70-6A7Z	Approved	[4]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
BMS-986205	DM3MAYQ	Melanoma	2C30	Phase 3	[5]
INCB24360	DMIJGT9	Urothelial carcinoma	2C92.0	Phase 3	[6]
NLG8189	DM0798Z	Melanoma	2C30	Phase 2/3	[5]
DN1406131	DMQFX8R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
HTI-1090	DMI4TEC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
KHK2455	DMLSUQ8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
LY3381916	DMONZ1L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PF-06840003	DMOX6EJ	Glioma	2A00.0	Phase 1	[9]

Drug(s) Affected By 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[10]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[11]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[12]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[13]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[14]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[15]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[16]
Hexachlorophene	DMLKSE0	Bacterial infection	1A00-1C4Z	Approved	[17]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[18]

Drug(s) Affected By Type I iodothyronine deiodinase (DIO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[19]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[24]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[3]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[25]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[26]

Drug(s) Affected By Thyroxine 5-deiodinase (DIO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[27]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[28]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[29]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[27]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[3]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[27]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[31]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[27]

Drug(s) Affected By Type II iodothyronine deiodinase (DIO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[32]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[33]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[34]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[24]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[35]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[30]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[36]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[37]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Indoleamine 2,3-dioxygenase 1 (IDO1)	TTZJYKH	I23O1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)	OTNAZVKB	3BHS1_HUMAN	Gene/Protein Processing	[2]
Thyroxine 5-deiodinase (DIO3)	OTNTITOT	IOD3_HUMAN	Gene/Protein Processing	[3]
Type I iodothyronine deiodinase (DIO1)	OTFYLYJ0	IOD1_HUMAN	Gene/Protein Processing	[3]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Gene/Protein Processing	[3]

References

• [1] Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
• [2] Inhibition of human and rat placental 3-hydroxysteroid dehydrogenase/(5,4)-isomerase activities by insecticides and fungicides: Mode action by docking analysis. Chem Biol Interact. 2023 Jan 5;369:110292. doi: 10.1016/j.cbi.2022.110292. Epub 2022 Dec 2.
• [3] Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
• [4] Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Incyte. Product Development Pipeline.
• [7] ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
• [8] Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [11] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [12] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [13] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [14] Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
• [15] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [16] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [17] The analysis of pesticides and fungicides in the inhibition of human and rat placental 3-hydroxysteroid dehydrogenase activity: Mode of inhibition and mechanism. Toxicol Lett. 2023 Apr 15;379:76-86. doi: 10.1016/j.toxlet.2023.03.002. Epub 2023 Mar 24.
• [18] Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. J Cell Biochem. 2003 Jul 1;89(4):755-70.
• [19] Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
• [20] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [21] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [22] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [23] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [24] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [25] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [26] Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid. 2005 Aug;15(8):835-40. doi: 10.1089/thy.2005.15.835.
• [27] Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology. 2006 Dec;147(12):5845-54. doi: 10.1210/en.2006-0590. Epub 2006 Aug 24.
• [28] MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. Endocr Relat Cancer. 2016 Mar;23(3):135-46. doi: 10.1530/ERC-15-0162.
• [29] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [30] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [31] Disturbance of the Dlk1-Dio3 imprinted domain may underlie placental Dio3 suppression and extracellular thyroid hormone disturbance in placenta-derived JEG-3 cells following decabromodiphenyl ether (BDE209) exposure. Toxicology. 2021 Jun 30;458:152837. doi: 10.1016/j.tox.2021.152837. Epub 2021 Jun 21.
• [32] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [33] The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes. 2007 Mar;56(3):767-76. doi: 10.2337/db06-1488.
• [34] Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology. 2009 Apr;150(4):1976-83. doi: 10.1210/en.2008-0938. Epub 2008 Nov 26.
• [35] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [36] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [37] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [38] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.